NCT00806520已完成不适用
Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control Addendum to: A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Long-Acting Release to Those of Sitagliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus Treated With Metformin (Study BCB106)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 5
研究概览
简要总结
Obtain Continuous Glucose Monitoring (CGM) data from individuals taking exenatide LAR, sitagliptin, or pioglitazone. The CGM measurements collected will help determine the characteristics of glucose control prior to treatment and during treatment.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years or older
- •type 2 diabetes
- •A1c 7.1 - 11
- •BMI 25 - 45
- •stable weight for 3 months before screening
- •fasting glucose < 280 at screening
- •stable dose of metformin for at least 2 months before screening
- •not being treated with or on a stable dose of hormone replacement therapy, oral contraceptives, anti-hypertensive agents, lipid lowering agents, thyroid replacement therapy, anti-depressants, drugs known to affect body weight
- •male or female, non-lactating, non-pregnant and willing to use birth control
- •lab values that are not clinically significant at screening
- •physical exam and ECG that are not clinically significant at screening
- •able to read, understand, and sign consent form
排除标准
- •liver disease
- •renal disease
- •cardiovascular disease
- •gastroparesis
- •cancer within 5 years of screening
- •macular edema
- •chronic infections
- •drug or alcohol abuse
- •fasting triglycerides > or = 600 at screening
- •previous exposure to exenatide LAR
- •has donated blood within 60 days of screening or is planning to donate during the study
- •has had a major surgery or blood transfusion within 2 months before screening
- •is currently being treated or is expecting to be treated with Byetta, Januvia, SU, TZD, GLP-1 analog, alpha-glucosidase inhibitor, meglitinide, nateglinide, symlin, insulin, systemic corticosteroids, lopid or rifampin
- •has received an investigational drug within 1 month before screening
- •has allergies or hypersensitivity to any component of the study drug
- •has previously had an adverse event related to TZD or Januvia
- •is an immediate family member of the study sight or directly affiliated
- •is employed by Amylin, Lilly or Alkermes
研究者
研究点 (5)
Loading locations...
相似试验
招募中
不适用
Continuous Glucose Monitoring for Glucose and Weight Management in Prediabetes and Non-severe Type 2 Diabetes: A Prospective Community-based (Workplace) Cohort StudyPreDiabetesDiabetes Mellitus, Type 2NCT06542627Kangbuk Samsung Hospital420
已完成
2 期
Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 DiabetesType 2 DiabetesNCT00993824HealthPartners Institute21
已完成
不适用
Continuous Glucose Monitoring of Hospitalized Patients With DiabetesGlucose, High BloodGlucose, Low BloodDiabetesDiabetes MellitusNCT04230694Baylor Research Institute40
已完成
不适用
Continuous Glucose Monitoring As Adjunct to Lifestyle Modification in PrediabetesPreDiabetesNCT04588896Chinese University of Hong Kong177
已完成
不适用
Tolerability, Acceptance, and Utility of Intermittent CGM Use in Youth With PrediabetesObesityInsulin ResistancePreDiabetesNCT05505565University of Alabama at Birmingham54